Page 15 - Read Online

Gauduchon et al. J Cancer Metastasis Treat 2019;5:72 I http://dx.doi.org/10.20517/2394-4722.2019.023 Page 9 of 9

Immunity by Unleashing Both T and NK Cells. Cell 2018;175:1731‑43.e13.
13. Cohen EEW, Harrington KJ, Hong DS, Mesia R, Brana I, et al. 1044OA phase Ib/II study (SCORES) of durvalumab (D) plus
danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous
cell carcinoma (RM‑HNSCC): Updated results. Ann Oncol 2018;29:mdy287.
14. Cohen EEW, Nabell L, Wong DJL, Day TA, Daniels GA, et al. Phase 1b/2, open label, multicenter study of intratumoral SD‑101 in
combination with pembrolizumab in anti‑PD‑1 treatment naïve patients with recurrent or metastatic head and neck squamous cell
carcinoma (HNSCC). J Clin Oncol 2019;37:6039.
15. Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, et al. Epacadostat plus Pembrolizumab in patients with advanced
solid tumors: phase I results from a multicenter, open‑label phase I/II trial (ECHO‑202/KEYNOTE‑037). J Clin Oncol
2018:JCO2018789602.
16. Taylor MH, Rasco DW, Brose MS, Vogelzang NJ, Richey SL, et al. A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients
with squamous cell carcinoma of the head and neck. J Clin Oncol 2018;36:6016.
17. Bell RB, Duhen R, Leidner RS, Curti BD, Ballesteros‑Merino C, et al. Neoadjuvant anti‑OX40 (MEDI6469) prior to surgery in head
and neck squamous cell carcinoma. J Clin Oncol 2018;36:6011.
18. Ogasawara M, Miyashita M, Yamagishi Y, Ota S. Phase I/II pilot study of Wilms’ tumor 1 peptide‑pulsed dendritic cell vaccination
combined with conventional chemotherapy in patients with head and neck cancer. Ther Apher Dial 2019;23:279‑88.
19. Haddad R, Concha‑Benavente F, Blumenschein G, Fayette J, Guigay J, et al. Nivolumab treatment beyond RECIST‑defined
progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: a subgroup analysis of a
randomized phase 3 clinical trial. Cancer 2019;125:3208‑18.
20. Saâda‑Bouzid E, Defaucheux C, Karabajakian A, Palomar Coloma V, Servois V, et al. Hyperprogression during anti‑PD‑1/PD‑L1
therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2017;28:1605‑11.
21. Foster CC, Kochanny S, Khattri A, Acharya R, Dekker A, et al. Association of immune‑related adverse events (irAEs) with improved
response, progression‑free survival, and overall survival for patients with metastatic head and neck cancer receiving anti‑PD‑1
therapy. J Clin Oncol 2018;36:6014.
22. De Cecco L, Nicolau M, Giannoccaro M, Daidone MG, Bossi P, et al. Head and neck cancer subtypes with biological and clinical
relevance: meta‑analysis of gene‑expression data. Oncotarget 2015;6:9627‑42.
23. Hanna GJ, Liu H, Jones RE, Bacay AF, Lizotte PH, et al. Defining an inflamed tumor immunophenotype in recurrent, metastatic
squamous cell carcinoma of the head and neck. Oral Oncol 2017;67:61‑9.
24. Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, et al. Hypermutated circulating tumor DNA: correlation with response to
checkpoint inhibitor‑based immunotherapy. Clin Cancer Res 2017;23:5729‑36.
25. Kirtane K, Muzaffar J, Slebos R, Chung CH. Association between human papillomavirus (HPV) status and duration of response of
anti‑programmed cell death protein‑1 (PD‑1) inhibitors in patients with recurrent/metastatic (R/M) head and neck squamous cell
carcinoma (HNSCC). J Clin Oncol 2019;37:6044.
26. Foster CC, Kochanny S, Khattri A, Acharya R, Dekker A, et al. Association of a baseline neutrophil‑to‑lymphocyte ratio (NLR) with
progression‑free and overall survival in head and neck cancer patients receiving anti‑PD‑1 therapy. J Clin Oncol 2018;36:6038.